# Treatment with L-type amino acid transporter 1 inhibitor JPH203 enhances protein synthesis in C2C12 myotubes

**Authors:** Junya Takegaki, Takaoki Saneyasu, Kazuhisa Honda

PMC · DOI: 10.1038/s41598-025-24534-2 · 2025-11-19

## TL;DR

Inhibiting LAT1 with JPH203 increases protein synthesis in muscle cells, possibly through mTOR signaling and glutamine accumulation.

## Contribution

Shows LAT1 inhibition enhances muscle protein synthesis via a novel, amino acid-independent mechanism.

## Key findings

- JPH203 increased protein synthesis without affecting mTORC1 markers like p70S6K or 4EBP1.
- JPH203-induced protein synthesis was suppressed by ATP-competitive mTOR inhibitor AZD8055.
- JPH203 treatment raised intracellular glutamine levels, potentially aiding protein synthesis.

## Abstract

Excessive muscle protein synthesis causes skeletal muscle hypertrophy. Essential amino acids are substrates for muscle proteins and stimulate muscle protein synthesis. Several essential amino acids are taken up into muscle cells through L-type amino acid transporter 1 (LAT1). However, LAT1 may influence protein synthesis in an amino acid uptake-independent manner. Here, we investigated the effects of LAT1 inhibition on protein synthesis in C2C12 myotubes and the associated mechanisms. JPH203 (50 μM), a selective inhibitor of LAT1, stimulated protein synthesis without changing expression of phosphorylated p70S6K (T389) and 4EBP1 (T37/46), an indicator of mTORC1 activity. Culturing in amino acid-free media did not suppress JPH203-induced protein synthesis. The mTORC1 inhibitor rapamycin (100 nM) did not suppress JPH203-induced protein synthesis. ATP-competitive mTOR inhibitor AZD8055 (1 μM) suppressed JPH203-induced protein synthesis. JPH203 treatment increased intracellular glutamine concentration. These results suggest that inhibition of LAT1 function augments muscle protein synthesis, possibly through the activation of rapamycin-insensitive mTOR signaling; elevated intracellular glutamine levels may contribute to the enhancement of muscle protein synthesis induced by LAT1 inhibition.

The online version contains supplementary material available at 10.1038/s41598-025-24534-2.

## Linked entities

- **Proteins:** SLC7A5 (solute carrier family 7 member 5), RPS6KB1 (ribosomal protein S6 kinase B1), EIF4EBP1 (eukaryotic translation initiation factor 4E binding protein 1), MTOR (mechanistic target of rapamycin kinase)
- **Chemicals:** JPH203 (PubChem CID 24853505), doxorubicin (PubChem CID 31703)

## Full-text entities

- **Genes:** RPS6KB1 (ribosomal protein S6 kinase B1) [NCBI Gene 6198] {aka PS6K, S6K, S6K-beta-1, S6K1, STK14A, p70 S6KA}, SLC7A5 (solute carrier family 7 member 5) [NCBI Gene 8140] {aka 4F2LC, CD98, D16S469E, E16, LAT1, MPE16}, EIF4EBP1 (eukaryotic translation initiation factor 4E binding protein 1) [NCBI Gene 1978] {aka 4E-BP1, 4EBP1, BP-1, PHAS-I}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}
- **Diseases:** muscle hypertrophy (MESH:C536106)
- **Chemicals:** glutamine (MESH:D005973), JPH203 (MESH:C548172), T389 (-), ATP (MESH:D000255), rapamycin (MESH:D020123), amino acid (MESH:D000596), AZD8055 (MESH:C546624), Essential amino acids (MESH:D000601)
- **Cell lines:** C2C12 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0188)

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12630651/full.md

---
Source: https://tomesphere.com/paper/PMC12630651